Capitolis Advisors LLC Amgen Inc Transaction History

Capitolis Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$230.71 - $256.74 $415,278 - $462,132	-1,800 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$219.27 - $242.57 $115 Million - $128 Million	-526,633 Reduced 99.66%	1,800 $435,000
Q4 2021 Feb 11, 2022	BUY	$198.88 - $227.6 $6.09 Million - $6.97 Million	30,632 Added 6.15%	528,433 $119 Million
Q3 2021 Nov 12, 2021	BUY	$212.27 - $248.7 $89 Million - $104 Million	419,152 Added 532.94%	497,801 $101 Million
Q2 2021 Aug 11, 2021	BUY	$233.58 - $259.14 $9.93 Million - $11 Million	42,493 Added 117.53%	78,649 $19.2 Million
Q1 2021 May 13, 2021	SELL	$221.91 - $258.6 $5.53 Million - $6.44 Million	-24,913 Reduced 40.79%	36,156 $9 Million
Q4 2020 May 07, 2021	BUY	$216.38 - $257.67 $13.2 Million - $15.7 Million	61,069 New	61,069 $14 Million

3,126

409M

7.56M

7.2M

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $142B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

Get notified when there are updates to the investment portfolio of Capitolis Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Capitolis Advisors LLC with notifications on news.